# Sequenta

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sequenta

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.sequentainc.com
- Total disclosed funding: $33M
- Latest round: Series C (Jul 2, 2013)
- Investors on record: 3

## About

Sequenta, Inc. is a biotechnology company focused on developing innovative diagnostics and therapeutic solutions that utilize the adaptive immune system for improved cancer detection and treatment.Sequenta, Inc. provides advanced immune-based solutions for cancer diagnostics. Founded in 2008, the company is headquartered in South San Francisco, US. In January 2015, Adaptive Biotechnologies acquired Sequenta for an undisclosed amount. Foresite Capital led Sequenta's latest funding round, a Series C round where the company raised USD 20.00 mn, totaling the amount raised to USD 20.00 mn across four deals.Sequenta, Inc. specializes in Immune Medicine, leveraging the adaptive immune system to develop innovative diagnostic and therapeutic solutions. Their flagship product, clonoSEQ®, provides a highly sensitive next-generation sequencing (NGS)-based assessment of minimal residual disease (MRD) for clinical practice and drug trials, facilitating the detection and quantification of MRD in hematological malignancies. The product supports healthcare providers, pharmaceutical companies, and research institutions, enhancing disease detection and treatment efficacy through precision medicine.Sequenta, Inc. generates revenue through direct sales and partnerships with healthcare institutions and pharmaceutical companies. The primary revenue streams come from the commercialization of the clonoSEQ® platform for MRD testing, structured around diagnostic services and products. This includes one-time fees for individual tests and potential subscription models for ongoing testing services, as well as collaborations with biopharma partners, which may involve milestone payments and royalties.Sequenta, Inc. is focused on developing new products aimed at enhancing immune-based diagnostics and therapeutics. Recent funding from their Series C round will support these initiatives. The company aims to expand into new markets across North America and Europe, enhancing their clinical offerings by leveraging their advanced technology. The acquisition by Adaptive Biotechnologies in January 2015 positions Sequenta for strategic growth in the biotech landscape.

## Funding rounds

- Series C, Jul 2, 2013, $20M — Index Ventures, Mohr Davidow Ventures, Foresite Capital
- Series B, Dec 8, 2010, $13M — Index Ventures, Mohr Davidow Ventures

## Investors

- Index Ventures (https://capitalatlas.ai/funds/index-ventures) — Series B, Series C
- Mohr Davidow Ventures (https://capitalatlas.ai/funds/mohr-davidow-ventures) — Series B, Series C
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series C